Literature DB >> 8794335

A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys.

K A Reimann1, J T Li, R Veazey, M Halloran, I W Park, G B Karlsson, J Sodroski, N L Letvin.   

Abstract

The utility of the simian immunodeficiency virus of macaques (SIVmac) model of AIDS has been limited by the genetic divergence of the envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) and the SIVs. To develop a better AIDS animal model, we have been exploring the infection of rhesus monkeys with chimeric simian/human immunodeficiency viruses (SHIVs) composed of SIVmac239 expressing HIV-1 env and the associated auxiliary HIV-1 genes tat, vpu, and rev. SHIV-89.6, constructed with the HIV-1 env of a cytopathic, macrophage-tropic clone of a patient isolate of HIV-1 (89.6), was previously shown to replicate to a high degree in monkeys during primary infection. However, pathogenic consequences of chronic infection were not evident. We now show that after two serial in vivo passages by intravenous blood inoculation of naive rhesus monkeys, this SHIV (SHIV-89.6P) induced CD4 lymphopenia and an AIDS-like disease with wasting and opportunistic infections. Genetic and serologic evaluation indicated that the reisolated SHIV-89.6P expressed envelope glycoproteins that resembled those of HIV-1. When inoculated into naive rhesus monkeys, SHIV-89.6P caused persistent infection and CD4 lymphopenia. This chimeric virus expressing patient isolate HIV-1 envelope glycoproteins will be valuable as a challenge virus for evaluating HIV-1 envelope-based vaccines and for exploring the genetic determinants of HIV-1 pathogenicity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794335      PMCID: PMC190741     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  20 in total

Review 1.  Animal models for the study of human immunodeficiency virus infections.

Authors:  N L Letvin
Journal:  Curr Opin Immunol       Date:  1992-08       Impact factor: 7.486

2.  Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins.

Authors:  J Li; C I Lord; W Haseltine; N L Letvin; J Sodroski
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

Review 3.  Pathology of simian immunodeficiency virus induced disease.

Authors:  A A Lackner
Journal:  Curr Top Microbiol Immunol       Date:  1994       Impact factor: 4.291

4.  Characterization of a discontinuous human immunodeficiency virus type 1 gp120 epitope recognized by a broadly reactive neutralizing human monoclonal antibody.

Authors:  M Thali; U Olshevsky; C Furman; D Gabuzda; M Posner; J Sodroski
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

5.  Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay.

Authors:  C Pachl; J A Todd; D G Kern; P J Sheridan; S J Fong; M Stempien; B Hoo; D Besemer; T Yeghiazarian; B Irvine
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-04-15

6.  Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.

Authors:  N Sullivan; Y Sun; J Li; W Hofmann; J Sodroski
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

7.  Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene.

Authors:  T Shioda; J A Levy; C Cheng-Mayer
Journal:  Nature       Date:  1991-01-10       Impact factor: 49.962

8.  An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of human immunodeficiency virus type 1.

Authors:  R Collman; J W Balliet; S A Gregory; H Friedman; D L Kolson; N Nathanson; A Srinivasan
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

9.  Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV).

Authors:  P A Luciw; E Pratt-Lowe; K E Shaw; J A Levy; C Cheng-Mayer
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

10.  Use of human leukocyte-specific monoclonal antibodies for clinically immunophenotyping lymphocytes of rhesus monkeys.

Authors:  K A Reimann; B C Waite; D E Lee-Parritz; W Lin; B Uchanska-Ziegler; M J O'Connell; N L Letvin
Journal:  Cytometry       Date:  1994-09-01
View more
  193 in total

1.  Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Authors:  S I Staprans; P J Dailey; A Rosenthal; C Horton; R M Grant; N Lerche; M B Feinberg
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time.

Authors:  P S Silverstein; G A Mackay; S Mukherjee; Z Li; M Piatak; J D Lifson; O Narayan; A Kumar
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection.

Authors:  Sampa Santra; Dan H Barouch; Marcelo J Kuroda; Jörn E Schmitz; Georgia R Krivulka; Kristin Beaudry; Carol I Lord; Michelle A Lifton; Linda S Wyatt; Bernard Moss; Vanessa M Hirsch; Norman L Letvin
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

4.  Simian-human immunodeficiency virus containing a human immunodeficiency virus type 1 subtype-E envelope gene: persistent infection, CD4(+) T-cell depletion, and mucosal membrane transmission in macaques.

Authors:  S Himathongkham; N S Halpin; J Li; M W Stout; C J Miller; P A Luciw
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Persistent pneumocystis colonization leads to the development of chronic obstructive pulmonary disease in a nonhuman primate model of AIDS.

Authors:  Timothy W Shipley; Heather M Kling; Alison Morris; Sangita Patil; Jan Kristoff; Siobhan E Guyach; Jessica E Murphy; Xiuping Shao; Frank C Sciurba; Robert M Rogers; Thomas Richards; Paul Thompson; Ronald C Montelaro; Harvey O Coxson; James C Hogg; Karen A Norris
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

6.  Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus.

Authors:  B Etemad-Moghadam; D Rhone; T Steenbeke; Y Sun; J Manola; R Gelman; J W Fanton; P Racz; K Tenner-Racz; M K Axthelm; N L Letvin; J Sodroski
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 7.  Strategies for an HIV vaccine.

Authors:  Norman L Letvin
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

8.  Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.

Authors:  Mayla Hsu; Janet M Harouse; Agegnehu Gettie; Clarisa Buckner; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

9.  Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen.

Authors:  Henry E Neuman de Vegvar; Rama Rao Amara; Lawrence Steinman; Paul J Utz; Harriet L Robinson; William H Robinson
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes.

Authors:  Tatsuhiko Igarashi; Yasuyuki Endo; Yoshiaki Nishimura; Charles Buckler; Reza Sadjadpour; Olivia K Donau; Marie-Jeanne Dumaurier; Ronald J Plishka; Alicia Buckler-White; Malcolm A Martin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.